GB
UPDATE: Gb Sciences Issues Shareholder Letter
16 mars 2022 15h01 HE | Gb Sciences
LAS VEGAS, March 16, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to...
GB
Gb Sciences Issues Summary Shareholder Letter
15 mars 2022 07h00 HE | Gb Sciences
LAS VEGAS, March 15, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to...
Gb Sciences
Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis
01 mars 2022 07h00 HE | Gb Sciences
LAS VEGAS, March 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has been issued a new patent today by the...
Gb Sciences
Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships
29 nov. 2021 07h00 HE | Gb Sciences
LAS VEGAS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company...
GB Sciences
Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety
01 nov. 2021 07h00 HE | Gb Sciences
LAS VEGAS, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has initiated new preclinical...